Main Article Content
Introduction: Hyperlipidemia is a leading cause of cardiovascular diseases (CHDs) with treatment ranging from dietary management and the use of antihyperlipidaemic drugs. The desire for anti-hyperlipidaemic drugs with less side effects has led to the screening of medical with anti-hyperlipidaemic properties.
Aim: The present study is aimed at evaluating the effects of hydromethanolic extracts of Dioscorea bulbifera on high fat diet, tyloxapol and dexamethasone induced hyperlipidaemia using Wistar rat models.
Methodology: Fifty five (55) adult male Wistar rats weighing 180-250 g were used for the study. Natural induction of hyperlipidaemia was done using a formulated High fat diet made from commercial rat chow and rendered cow fat while chemical induction of hyperlipidaemia was done using tyloxapol (200 mg/kg) and dexamethasone (20 mg/kg). The Wistar rats where divided into eleven (11) groups comprising four (5) control groups and seven (6) experimental groups. The extracts were used to treat the hyperlipidaemic rats at 200 mg/kg and 400 mg/kg while Simvastatin was used as a standard. Blood samples of the animals were analyzed for Total cholesterol (TC), Triglycerides (TG), High density lipoproteins (HDL), Low density lipoproteins (LDL), Very low density lipoprotein (VLDL) and Serum glucose were determined by standard enzymatic methods.
Results: The results indicate that the hyperlipidaemic rats treated with extracts of Dioscorea bulbifera had significantly reduced TC, TG, LDL, VLDL and serum glucose compared with the control (untreated hyperlipidaemic rats) (P<0.05). In the same way, the HDL was found to be significantly higher among the treated hyperlipidaemic rats compared with the untreated controls.
Conclusion: The present study shows that hydromethanolic extracts of Dioscorea bulbifera has a possible antihyperlipidaemic potentials as demonstrated by its ability to significantly improve lipid profile and lower serum glucose levels in hyperlipidaemic rat models.
Shattat GF. A review article on hyperlipidemia: Types, treatments and new drug targets. Biomedical and Pharmaco-logy Journal. 2015;7(1):399-409.
Ginghina C, Bejan I, Ceck C. Modern risk stratification in coronary heart disease. Journal of Medicine and Life. 2011;4(4): 377-86.
Onwe P, Folawiyo M, Anyigor-Ogah C, Umahi G, Okorocha A, Afoke A. Hyperlipidemia: Etiology and possible control. Journal of Dental Medical Sciences. 2015;14(10):93-100.
Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GJ, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Canadian Journal of Cardiology. 2013;29(2):151-67.
Singh R, Nain S. A mini-review on hyperlipidemia: Common clinical problem. Interventional Cardiology Journal. 2018; 4(3(10):1-3.
Kumar VS, Inamdar MN, Viswanatha GL. Protective effect of lemongrass oil against dexamethasone induced hyperlipidemia in rats: possible role of decreased lecithin cholesterol acetyl transferase activity. Asian Pacific Journal of Tropical Medicine. 2011;4(8):658-60.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. The lancet. 2005; 365(9455):217-23.
Zamani M, Rahimi AO, Mahdavi R, Nikbakhsh M, Jabbari MV, Rezazadeh H, et al. Assessment of anti-hyperlipidemic effect of Citrullus colocynthis. Revista Brasileira de Farmacognosia. 2007;17(4): 492-6.
Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials. BMJ. 1990;301(6747): 309-14.
Assmann G, Cullen P, Jossa F, Lewis B, Mancini M. Coronary heart disease: Reducing the risk: The scientific back-ground to primary and secondary prevention of coronary heart disease a worldwide view. Arteriosclerosis, throm-bosis and Vascular Biology. 1999;19(8): 1819-24.
Farmer JA, Gotto AM. Antihyperlipidaemic agents. Drug safety. 1994;11(5):301- 9.
Katan M. Dietary management of the hyperlipidaemic patient. Lipid Insight. 1991;1:2-5.
Pragda SS, Kuppast IJ, Mankani KL, Ramesh L. Evaluation of antihyperli-pidemic activity of leaves of Portulaca oleracea linn against dexamethasone induced hyperlipidemia in rats. International Journal of Pharmacy and Pharmaceutical Sciences. 2012;4(4):279-83.
Steiner A, Weisser B, Vetter W. A comparative review of the adverse effects of treatments for hyperlipidaemia. Drug Safety. 1991;6(2):118-30.
Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Medical Toxicology and Adverse Drug Experience. 1987;2(1): 10-32.
Tonstad S, Pometta D, Erkelens D, Ose L, Moccetti T, Schouten J, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. European Journal of Clinical Pharmacology. 1994; 46(5):405-10.
Mbiantcha M, Kamanyi A, Teponno RB, Tapondjou AL, Watcho P, Nguelefack TB. Analgesic and anti-inflammatory properties of extracts from the bulbils of Dioscorea bulbifera L. var sativa (Dioscoreaceae) in mice and rats. Evidence-Based Complementary and Alternative Medicine. 2010;2011:1-9.
Ghosh S, Parihar VS, More P, Dhavale DD, Chopade BA. Phytochemistry and therapeutic potential of medicinal plant: Dioscorea bulbifera. Medicinal Chemistry. 2015;5:154-9.
Martin FW. Tropical yams and their potential. Part 2. Dioscorea bulbifera. Virginia: Agricultural Research Service; 1974.
Odugbemi T. A textbook of medicinal plants from Nigeria. Lagos: University of Lagos Press; 2008.
Okeke EC, Eneobong HN, Uzuegbunam AO, Ozioko A, Kuhnlein H. Igbo traditional food system: Documentation, uses and research needs. Pakistan Journal of Nutrition. 2008;7(2):365-76.
Subhash C, Sarla S, Abhay MP, Anoop B. Nutritional profile and phytochemical screening of Garhwal Himalaya medicinal plant Dioscorea bulbifera. International Research Journal of Pharmacy. 2012;3(5): 289-94.
Cogne AL. Phytochemical investigation of plants used in African medicine: Dioscorea sylvatica (Dioscoreaceae), Urginea altissima (Liliaceae), Jamesbrittenia fodina and Jamesbrittenia elegantissima (Scrophulariaceae). Doctorat Theses University of Lausanne, Lausanne; 2002.
Guan XR, Zhu L, Xiao ZG, Zhang YL, Chen HB, Yi T. Bioactivity, toxicity and detoxification assessment of Dioscorea bulbifera L.: A comprehensive review. Phytochemistry Reviews. 2017;16(3):573-601.
Chinko BC, Dapper DV, Adienbo OM, Egwurugwu JN, Joffa PPK. Preliminary assessment of the effects of hydro-methanolic extract of dioscorea bulbifera on haematological parameters and serum electrolytes of wistar rats. European Journal of Biomedical and Pharmaceutical Sciences. 2016;3(10):83-7.
Panduraju T, Bitra VR, Vemula SK, Reddy PRV. Wound healing activity of Dioscorea bulbifera Linn. Journal of Pharmacy Research. 2010;3(12):3138-9.
R Vasanthi H, ShriShriMal N, K Das D. Phytochemicals from plants to combat cardiovascular disease. Current medicinal chemistry. 2012;19(14):2242-51.
Suriyavathana M, Indupriya S. Screening of antioxidant potentials in Dioscorea bulbifera. International Journal of Pharmacy and Life Sciences. 2011;2(4): 661-4.
Balasubramanian J, Dhanalakshmi R, Jibnomen P, Manimekalai P. A preclinical evaluation on antioxidant and gastro-protective effect of Dioscorea bulbifera in Wistar rats. Indian Journal of Innovations and Developments. 2012;1(3):149-54.
Gao H, Hou B, Kuroyanagi M, Wu L. Constituents from anti-tumor-promoting active part of Dioscorea bulbifera L. in JB6 mouse epidermal cells. Asian Traditional Medicine. 2007;2(3):104-9.
Gao H, Kuroyanagi M, Wu L, Kawahara N, Yasuno T, Nakamura Y. Antitumor-promoting constituents from Dioscorea bulbifera L. in JB6 mouse epidermal cells. Biological and Pharmaceutical Bulletin. 2002;25(9):1241-3.
Kuete V, BetrandTeponno R, Mbaveng AT, Tapondjou LA, Meyer JJM, Barboni L, et al. Antibacterial activities of the extracts, fractions and compounds from Dioscorea bulbifera. BioMed Central Complementary and Alternative Medicine. 2012;12(1):1.
Adeosun OM, Arotupin DJ, Toba OA, Adewole A. Antibacterial activities and phytochemical properties of extracts of Dioscorea bulbifera Linn (Air Potatoe) tubers and peels against some pathogenic bacteria; 2016.
Chinko BC, Dapper DV, Adienbo OM, Egwurugwu JN, Uchefuna RC. Biochemical evaluation of the effects of hydromethanolic extracts of Dioscorea bulbifera in wistar rats. IOSR Journal of Dental and Medical Sciences. 2016;5(9): 105-10.
Ahmed Z, Chishti MZ, Johri RK, Bhagat A, Gupta KK, Ram G. Antihyperglycemic and antidyslipidemic activity of aqueous extract of Dioscorea bulbifera tubers. Diabetologia Croatica. 2009;38(3):63-72.
Odebiyi OO, Sofowora EA. Phytochemical screening of Nigerian medicinal plants II. Journal of Natural Products (Lloydia). 1977;41(3):234-46.
Gajda AM. High fat diets for diet-induced obesity models. Open Source Diets; 2009.
Ngoc TH, Ngoc QN, Tran A, Phung NV. Hypolipidemic effect of extracts from Abelmoschus esculentus L. (Malvaceae) on Tyloxapol-induced hyperlipidemia in mice. J Pharm Sci. 2008;35:42-6.
Bertges LC, Mourão Jr CA, Souza JB, Cardoso VAC. Hyperlipidemia induced by Triton WR1339 (Tyloxapol) in Wistar rats. Braz J Med Sci Health. 2011;1:32-4.
Ansarullah A, Jadeja R, Thounaojam M, Patel V, Devkar R, Ramachandran A. Antihyperlipidemic potential of a polyherbal preparation on triton WR 1339 (Tyloxapol) induced hyperlipidemia: A comparison with lovastatin. International Journal of Green Pharmacy (IJGP). 2009;3(2).
Nvl SR, Aveti S, Anjum M. Anti-hyper-lipidemic activity of methanolic extract of Syzygium alternifolium bark against high-fat diet and dexamethasone-induced hyperlipidemia in rats. Asian J Pharm Clin Res. 2015;8(6):165-8.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracen-trifuge. Clinical Chemistry. 1972;18(6):499-502.
Crook M. Clinical Chemistry & Metabolic Medicine. London: Edwarld Arnold publishers Ltd.; 2006.
Sheikh N, Kumar Y, Misra A, Pfoze L. Phytochemical screening to validate the ethnobotanical importance of root tubers of Dioscorea species of Meghalaya, North East India. Journal of Medicinal Plants. 2013;1(6):62-9.
Malode UG, Mohammad N, Quazi SA, Mahajan DT, Masand V. Phytochemical investigations of Dioscorea bulbifera linn. Indian Journal of Research in Pharmacy and Biotechnology. 2015;3:20-3.
Okon JE, Ofeni AA. Antidiabetic effect of Dioscorea bulbifera on alloxan induced diabetic rats. CIBTech Journal of Pharmaceutical Sciences. 2013;2(1):14-5.
Cayen MN, Dvornik D. Effect of diosgenin on lipid metabolism in rats. Journal of lipid research. 1979;20(2):162-74.
Jyothishwaran G, Seetharam YN. Biotrans-formation of cholesterol to diosgenin by freely suspended and immobilised cells of Dioscorea bulbifera L. Journal of Asian Natural Products Research. 2008;10(2): 139-45.
Jayachandran KS, Vasanthi AHR, Gurusamy N. Steroidal saponin diosgenin from Dioscorea bulbifera protects cardiac cells from hypoxia-reoxygenation injury through modulation of pro-survival and pro-death molecules. Pharmacognosy Magazine. 2016;12(1):14-20.
Ghosh S, More P, Derle A, Patil AB, Markad P, Asok A, et al. Diosgenin from Dioscorea bulbifera: Novel hit for treatment of type II diabetes mellitus with inhibitory activity against α-amylase and α-glucosidase. PloS One. 2014;9(9): e106039.
Estiasih T, Ariestiningsih AD, Wardani NAK. The effect of crude diosgenin extract from purple and yellow greater yams (Dioscorea alata) on the lipid profile of dyslipidemia rats. Emirates Journal of Food and Agriculture. 2016;28(7):506-12.
Elekofehinti OO, Omotuyi IO, Kamdem JP, Ejelonu OC, Alves GV, Adanlawo IG, et al. Saponin as regulator of biofuel: Implication for ethnobotanical management of diabetes. Journal of Physiology and Biochemistry. 2014;70(2):555-67.
Sidhu GS, Oakenfull DG. A mechanism for the hypocholesterolaemic activity of saponins. British Journal of Nutrition. 1986;55(3):643-9.
Oakenfull D, Sidhu GS. Could saponins be a useful treatment for hypercholestero-laemia? European Journal of Clinical Nutrition. 1990;44(1):79-88.
Malloy MJ, Kane JP. Basic & Clinical Pharmacology: Agents used in dyslipidemia. New York: McGraw Hill Companies; 2012.
Chantre P, Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine. 2002;9(1):3-8.
Wolfram S, Raederstorff D, Preller M, Wang Y, Teixeira SR, Riegger C, et al. Epigallocatechin gallate supplementation alleviates diabetes in rodents. The Journal of nutrition. 2006;136(10):2512-8.
Sudheesh S, Vijay Kumar S, Sandhya C, Vijayalakshmi NR. Toxic effects of condensed tannins from Solanum melongena on rats. Journal of Ecotoxico-logy and Environmental Monitoring. 1996; 6:221.
Bahorun T, Neergheen VS, Aruoma OI. Phytochemical constituents of Cassia fistula. African Journal of Biotechnology. 2005;4(13).
Patel D, Patel K, Patel U, Thounaojam M, Jadeja R, Padate G, et al. Assessment of lipid lowering effect of Sida rhomboidea. Roxb methanolic extract in experimentally induced hyperlipidemia. Journal of Young Pharmacists. 2009;1(3):233-8.
Otunola GA, Oloyede OB, Oladiji AT, Afolayan AA. Effects of diet-induced hyper-cholesterolemia on the lipid profile and some enzyme activities in female Wistar rats. Afr J Biochem Res. 2010;4(6):149- 54.
Sudhahar V, Kumar SA, Sudharsan PT, Varalakshmi P. Protective effect of lupeol and its ester on cardiac abnormalities in experimental hypercholesterolemia. Vascular Pharmacology. 2007;46(6):412- 8.
Pessoa L, Rego T, Asht L, Rego I, Fortunato M, Feijo M. Serum and liver lipids distributions in streptozotocin induced diabetic rat treated with diet containing Yam (Dioscorea bulbifera) flour. Nutrición Hospitalaria. 2015;31(4):1647- 53.
Ghosh S, Ahire M, Patil S, Jabgunde A, Bhat Dusane M, Joshi BN, et al. Antidiabetic activity of Gnidia glauca and Dioscorea bulbifera: potent amylase and glucosidase inhibitors. Evidence-Based Complementary and Alternative Medicine. 2011;2012:1-10.
Kim JS, Kwon CS, Son KH. Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid. Bioscience, Biotechnology, and Biochemistry. 2000;64(11):2458- 61.
Rubilar M, Jara C, Poo Y, Acevedo F, Gutierrez C, Sineiro J, et al. Extracts of maqui (Aristotelia chilensis) and murta (Ugni molinae Turcz.): Sources of antioxidant compounds and α-glucosidase/ α-amylase inhibitors. Journal of Agricultural and Food Chemistry. 2011;59(5):1630- 7.
Tadera K, Minami Y, Takamatsu K, Matsuoka T. Inhibition of α-Glucosidase and α-Amylase by Flavonoids. Journal of Nutritional Science and Vitaminology. 2006;52(2):149-53.
Franco OL, Rigden DJ, Melo FR, Grossi‐de‐Sá MF. Plant α‐amylase inhibitors and their interaction with insect α‐amylases. European Journal of Biochemistry. 2002;269(2):397-412.
Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs. 1999;57(1):19-29.
Swanston-Flatt SK, Day C, Bailey CJ, Flatt P. Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetologia. 1990;33(8): 462-4.
Oyedemi SO, Yakubu MT, Afolayan AJ. Antidiabetic activities of aqueous leaves extract of Leonotis leonurus in streptozotocin induced diabetic rats. Journal of Medicinal Plants Research. 2011;5(1):119-25.
Sharma SB, Nasir A, Prabhu KM, Murthy PS. Antihyperglycemic effect of the fruit-pulp of Eugenia jambolana in experimental diabetes mellitus. Journal of Ethno-pharmacology. 2006;104(3):367-73.
Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmeno-pausal women in Enugu, Nigeria. African health sciences. 2010;10(3):248-52.
Dobiás̆ová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL). Clinical biochemistry. 2001; 34(7):583-8.
Onat A, Can G, Kaya H, Hergenç G. Atherogenic index of plasma (log 10 triglyceride/high-density lipoprotein− cholesterol) predicts high blood pressure, diabetes, and vascular events. Journal of clinical lipidology. 2010;4(2):89-98.
Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Medical Journal of the Islamic Republic of Iran. 2015;29:240.
Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyagi S. Atherogenic index of plasma, castelli risk index and atherogenic coefficient-new parameters in assessing cardiovascular risk. Int J Pharm Biol Sci. 2013;3(3):359-64.